Influenza a infections pipeline review, h1 2014


Published on

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Published in: Business, Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Influenza a infections pipeline review, h1 2014

  1. 1. Influenza A Infections - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Influenza A Infections The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Influenza A Infections pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Influenza A Infections Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 8 list Of Figures 9 introduction 10 global Markets Direct Report Coverage 10 influenza A Infections Overview 11 therapeutics Development 12 pipeline Products For Influenza A Infections Overview 12 pipeline Products For Influenza A Infections Comparative Analysis 13 influenza A Infections Therapeutics Under Development By Companies 14 influenza A Infections Therapeutics Under Investigation By Universities/institutes 17 influenza A Infections Pipeline Products Glance 18 clinical Stage Products 18 early Stage Products 19 influenza A Infections Products Under Development By Companies 20 influenza A Infections Products Under Investigation By Universities/institutes 22 influenza A Infections Companies Involved In Therapeutics Development 23 f. Hoffmann-la Roche Ltd. 23 autoimmune Technologies, Llc 24 glaxosmithkline Plc 25 inovio Pharmaceuticals, Inc. 26 vertex Pharmaceuticals Incorporated 27 crucell N.v. 28 hemispherx Biopharma, Inc. 29 amarillo Biosciences, Inc. 30 siga Technologies, Inc. 31 vironova Ab 32 curevac Gmbh 33 pt Bio Farma 34 viroblock S.a. 35 innate Therapeutics Limited 36 chimerix, Inc. 37 Influenza A Infections - Pipeline Review, H1 2014
  2. 2. theraclone Sciences, Inc. 38 immune Targeting Systems (its) Ltd. 39 sinovac Biotech Ltd. 40 microbiotix, Inc. 41 alios Biopharma, Inc. 42 immuneregen Biosciences, Inc. 43 vivaldi Biosciences Inc. 44 humabs Biomed Sa 45 microgen Scientific Industrial Company For Immunobiological Medicines 46 influenza A Infections Therapeutics Assessment 47 assessment By Monotherapy Products 47 assessment By Target 48 assessment By Mechanism Of Action 51 assessment By Route Of Administration 54 assessment By Molecule Type 56 drug Profiles 59 diridavumab - Drug Profile 59 product Description 59 mechanism Of Action 59 r&d Progress 59 interferon Alfa - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 fp-01 - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 cr-8020 - Drug Profile 64 product Description 64 mechanism Of Action 64 r&d Progress 64 tcn-032 - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 midodrine Hydrochloride - Drug Profile 67 product Description 67 mechanism Of Action 67 r&d Progress 67 vx-787 - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 avian Flu Vaccine - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 rg-7745 - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 influenza A H7n7 Vaccine - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 vis-410 - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 orvax - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 gsk-3206641-a - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 Influenza A Infections - Pipeline Review, H1 2014
  3. 3. gsk-3206640a - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 h7n9 Vaccine - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 homspera - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 rintatolimod - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 interferon Alfa-n3 (human Leukocyte Derived) - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 drug For Influenza A Infections - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 mis-416 - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 flufirvitide-3 - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 nucleozin - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 small Molecule For Influenza A - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 et-001 - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 cr-8043 - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 fi-6 - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 pam2cys Vaccine - Drug Profile 92 product Description 92 mechanism Of Action 92 r&d Progress 92 dna Vaccine For H7n9 Universal Influenza - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 influenza Vaccine - Drug Profile 94 product Description 94 mechanism Of Action 94 r&d Progress 94 peptides For Influenza Infections - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 Influenza A Infections - Pipeline Review, H1 2014
  4. 4. gamma-flu - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 influenza Drug Discovery Program - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 monoclonal Antibody To Inhibit Hemagglutinin For Influenza A Virus Infection - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 small Molecule To Inhibit Hemagglutinin For Influenza A - Drug Profile 99 product Description 99 mechanism Of Action 99 r&d Progress 99 drug For Influenza A - Drug Profile 100 product Description 100 mechanism Of Action 100 r&d Progress 100 al-18 - Drug Profile 101 product Description 101 mechanism Of Action 101 r&d Progress 101 mbx-2329 - Drug Profile 102 product Description 102 mechanism Of Action 102 r&d Progress 102 mbx-2546 - Drug Profile 104 product Description 104 mechanism Of Action 104 r&d Progress 104 fluinhibit - Drug Profile 105 product Description 105 mechanism Of Action 105 r&d Progress 105 drug For Influenza Virus - Drug Profile 106 product Description 106 mechanism Of Action 106 r&d Progress 106 vaccines For Influenza A H7n9 Infections - Drug Profile 107 product Description 107 mechanism Of Action 107 r&d Progress 107 influenza A Infections Recent Pipeline Updates 108 influenza A Infections Dormant Projects 120 influenza A Infections Discontinued Products 121 influenza A Infections Product Development Milestones 122 featured News & Press Releases 122 oct 24, 2013: Baxter's Vepacel Receives Chmp Positive Opinion 122 oct 21, 2013: Nanoviricides Says Early Results Indicate That Flucide Was Extremely Safe In A Non-glp Small Animal Tox Study 122 oct 07, 2013: Nanoviricides Announces Initiation Of Toxicology Study Of Flucide 123 sep 09, 2013: Theraclone Sciences Announces Universal Therapeutic Antibody For Influenza A Demonstrates Reductions In Clinical Symptoms Score And Viral Load In A Phase 2a Human Viral Challenge Study 124 sep 09, 2013: Visterra Presents Prophylactic And Therapeutic Efficacy Data Of Vis410 Against Multiple Influenza Strains With Pandemic Potential 125 aug 26, 2013: Hemispherx Announces Biosecurity Program To Potentially Reduce Pandemic Influenza Threat 126 aug 05, 2013: Nanoviricides Signs A Non-disclosure Agreement With The Lovelace Respiratory Research Institute For Ind-enabling Efficacy Studies On Flucide And For Testing Its Novel Drug Candidates Against The Highly Lethal Mers Human Coronavirus 127 oct 25, 2012: Theraclone Sciences Initiates Phase Ii Viral Challenge Clinical Study Of Therapeutic Antibody For Treatment Of Influenza A 127 oct 18, 2012: Sanofi Pasteur's Sbla For New Four-strain Influenza Vaccine Accepted For Review By Fda 128 sep 17, 2012: Immune Targeting Systems Announces Positive Phase I Data For Flunisyn 129 appendix 131 methodology 131 coverage 131 secondary Research 131 primary Research 131 expert Panel Validation 131 Influenza A Infections - Pipeline Review, H1 2014
  5. 5. contact Us 132 disclaimer 132 ResearchMoz( is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: Website: Influenza A Infections - Pipeline Review, H1 2014